AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7722710 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (for males aged 14-19 years)
Number of subjects: 364
Study 7722710 — intervention group
Group type: COMPARATOR
Intervention: Fresco (for males aged 14-19 years)
Number of subjects: 364
Study 7722710 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (for females aged 14-19 years)
Number of subjects: 364
Study 2126727 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nitroglycerin patches (10mg/24hrs)
Number of subjects: 16
Study 2126727 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 16
Study 7237200 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally two hours pre-operatively
Number of subjects: 45
Study 7237200 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate 0.3 M solution 30 ml orally
Number of subjects: 45
Study 7237200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no agent to decrease gastric acidity)
Number of subjects: 45
Study 30009626 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intensive Behavioral Intervention (EIBI), 35 hours per week for 3 years.
Number of subjects: 94
Study 30009626 — intervention group
Group type: COMPARATOR
Intervention: Standard early childhood services as usual (SAU).
Number of subjects: 94
Study 31074598 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported work-related injuries
Number of subjects: 300
Study 31074598 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported musculoskeletal disorders
Number of subjects: 300
Study 31074598 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific types of injuries
Number of subjects: 300
Study 31074598 — intervention group
Group type: EXPERIMENTAL
Intervention: Association with demographic variables
Number of subjects: 300
Study 25927716 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive treatment (ECT)
Number of subjects: 40
Study 25927716 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers not receiving ECT (Control Group 1)
Number of subjects: 40
Study 25927716 — intervention group
Group type: COMPARATOR
Intervention: Patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF) (Control Group 2)
Number of subjects: 40
Study 23702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (8 weekly sessions of 90 minutes each)
Number of subjects: 240
Study 23702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) (8 weekly sessions of 90 minutes each)
Number of subjects: 240
Study 23702050 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (6 months)
Number of subjects: 240
Study 23702050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure and EMDR
Number of subjects: 240
Study 20425129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cannula stillete (IVCS)
Number of subjects: 45
Study 20425129 — intervention group
Group type: COMPARATOR
Intervention: Conventional awl
Number of subjects: 45
Study 19536452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily) and omeprazole (20 mg once daily) for 18 months
Number of subjects: 22
Study 19536452 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study 17366126 — intervention group
Group type: EXPERIMENTAL
Intervention: keepin' it REAL program
Number of subjects: 4622
Study 14718679 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa plus entacapone
Number of subjects: 300000
Study 14718679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300000
Study 11433128 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 35mg (high dose)
Number of subjects: 0
Study 11433128 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 5mg (low dose)
Number of subjects: 0
Study 9622936 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparins (LMWH) at home followed by oral anticoagulant
Number of subjects: 0
Study 9622936 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) in hospital followed by oral anticoagulant
Number of subjects: 0
Study 9773138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion for 20 hours with a bolus dose before aortic clamping
Number of subjects: 100
Study 9773138 — intervention group
Group type: COMPARATOR
Intervention: Control group without lidocaine infusion
Number of subjects: 100
Study 2626338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse, 15 ml, 3 times daily
Number of subjects: 47
Study 2626338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 2626338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 47
Study 1107960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of ten units of regular insulin twice a day for five days
Number of subjects: 14
Study 1107960 — intervention group
Group type: COMPARATOR
Intervention: Variety of topical therapies other than insulin
Number of subjects: 14
Study 30940421 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 117
Study 30940421 — intervention group
Group type: COMPARATOR
Intervention: Surgery (S)
Number of subjects: 117
Study 30940421 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued smoking after RT
Number of subjects: 117
Study 28542081 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 2310
Study 28542081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2310
Study 26431124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular facet joint injections
Number of subjects: 52
Study 26431124 — intervention group
Group type: EXPERIMENTAL
Intervention: Best usual care
Number of subjects: 52
Study 23872690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1495
Study 23872690 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD) only
Number of subjects: 1495
Study 22056634 — intervention group
Group type: EXPERIMENTAL
Intervention: High fear appeal
Number of subjects: 321
Study 22056634 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium fear appeal
Number of subjects: 321
Study 22056634 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain frame
Number of subjects: 321
Study 22056634 — intervention group
Group type: COMPARATOR
Intervention: Low fear appeal
Number of subjects: 321
Study 22056634 — intervention group
Group type: COMPARATOR
Intervention: Loss frame
Number of subjects: 321
Study 22056634 — intervention group
Group type: COMPARATOR
Intervention: Education (control group)
Number of subjects: 321
Study 22056634 — intervention group
Group type: COMPARATOR
Intervention: Non-education (control group)
Number of subjects: 321
Study 19483278 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate binders
Number of subjects: 0
Study 17110816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glycine infusion
Number of subjects: 13
Study 17110816 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 13
Study 15243887 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Balloon Dilation (EPBD)
Number of subjects: 200
Study 15243887 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 200
Study 11302905 — intervention group
Group type: EXPERIMENTAL
Intervention: Near patient testing for H pylori and open access endoscopy for patients with positive results
Number of subjects: 478
Study 11302905 — intervention group
Group type: COMPARATOR
Intervention: Acid suppressing drugs or specialist referral at general practitioner's discretion
Number of subjects: 478
Study 9287573 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 66
Study 9287573 — intervention group
Group type: COMPARATOR
Intervention: Nurse-controlled analgesia (NCA)
Number of subjects: 66
Study 8346946 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U/kg r‐HuEpo subcutaneously three times a week from week 3 to week 7
Number of subjects: 29
Study 8346946 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 infants)
Number of subjects: 29
Study 3953477 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopheryl acetate (all‐rac‐alpha‐tocopheryl acetate)
Number of subjects: 0
Study 3953477 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐alpha‐tocopheryl acetate (RRR‐alpha‐tocopheryl acetate)
Number of subjects: 0
Study 3953477 — intervention group
Group type: EXPERIMENTAL
Intervention: Both forms of vitamin E
Number of subjects: 0
Study 31672387 — intervention group
Group type: EXPERIMENTAL
Intervention: LAI‐risperidone (LAI‐R)
Number of subjects: 305
Study 31672387 — intervention group
Group type: COMPARATOR
Intervention: daily oral second‐generation antipsychotics (SGA)
Number of subjects: 305
Study 31672387 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional withdrawal
Number of subjects: 305
Study 29605716 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 162
Study 29605716 — intervention group
Group type: COMPARATOR
Intervention: No transplant
Number of subjects: 162
Study 27564579 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) for 60–90 seconds
Number of subjects: 200
Study 27564579 — intervention group
Group type: COMPARATOR
Intervention: Umbilical cord milking (UCM)
Number of subjects: 200
Study 27564579 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 200
Study 23765630 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 50 mg
Number of subjects: 0
Study 23765630 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 100 mg
Number of subjects: 0
Study 23765630 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant 200 mg
Number of subjects: 0
Study 23765630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23036028 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU) care
Number of subjects: 99
Study 23036028 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study 19287303 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (300 microg twice weekly)
Number of subjects: 25
Study 19287303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 17452090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplements to lower homocysteine
Number of subjects: 253
Study 17452090 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest data with a 1-year interval
Number of subjects: 253
Study 17452090 — intervention group
Group type: EXPERIMENTAL
Intervention: Full sample analysis
Number of subjects: 253
Study 17452090 — intervention group
Group type: EXPERIMENTAL
Intervention: Age stratification
Number of subjects: 253
Study 15118196 — intervention group
Group type: EXPERIMENTAL
Intervention: CordyMax Cs-4 (3 g/d)
Number of subjects: 22
Study 15118196 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 22
Study 11486455 — intervention group
Group type: EXPERIMENTAL
Intervention: Eberconazole 1% cream
Number of subjects: 157
Study 11486455 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% cream
Number of subjects: 157
Study 9571333 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (insulin therapy alone)
Number of subjects: 153
Study 9571333 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 153
Study 8153573 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol HCl
Number of subjects: 48
Study 8153573 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% delmopinol HCl
Number of subjects: 48
Study 8153573 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% delmopinol HCl
Number of subjects: 48
Study 8153573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3360731 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 1
Study 3360731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 7238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual signals presented at two spatial locations (15.5 degrees and 29.1 degrees)
Number of subjects: 0
Study 7238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual signals presented with room illumination
Number of subjects: 0
Study 7238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual signals presented without room illumination
Number of subjects: 0
Study 7238679 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimulus triggering eye-hand-arm motion
Number of subjects: 0
Study 31220010 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching and progressive resistance exercise for lower extremities for 16 weeks, followed by a 16-week maintenance program
Number of subjects: 37
Study 31220010 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 37
Study 28864699 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine balloon tamponade with a condom-catheter device and misoprostol
Number of subjects: 116
Study 28864699 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone (control)
Number of subjects: 116
Study 28864699 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine balloon tamponade with misoprostol
Number of subjects: 116
Study 26485379 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for behavioral changes (group 1)
Number of subjects: 41
Study 26485379 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and an occlusal appliance (group 2)
Number of subjects: 41
Study 23864781 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel double pants (NDP)
Number of subjects: 160
Study 23864781 — intervention group
Group type: COMPARATOR
Intervention: Conventional single pants (CSP)
Number of subjects: 160
Study 22858075 — intervention group
Group type: EXPERIMENTAL
Intervention: ADR + carvedilol
Number of subjects: 50
Study 22858075 — intervention group
Group type: COMPARATOR
Intervention: ADR
Number of subjects: 50
Study 19683115 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystal Light Lemonade
Number of subjects: 23
Study 19683115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropical Punch Kool‐Aid
Number of subjects: 23
Study 19683115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropicana orange juice
Number of subjects: 23
Study 19683115 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 23
Study 17478154 — intervention group
Group type: COMPARATOR
Intervention: Endothelium-dependent (flow-mediated dilation [FMD]) in patients with AF
Number of subjects: 46
Study 17478154 — intervention group
Group type: COMPARATOR
Intervention: Endothelium-independent (nitroglycerin-mediated dilation [NMD]) in patients with AF
Number of subjects: 46
Study 17478154 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD after restoration of sinus rhythm at 24 hours
Number of subjects: 46
Study 17478154 — intervention group
Group type: EXPERIMENTAL
Intervention: FMD after restoration of sinus rhythm at 1 month
Number of subjects: 46
Study 17478154 — intervention group
Group type: EXPERIMENTAL
Intervention: NMD after restoration of sinus rhythm at 24 hours
Number of subjects: 46
Study 17478154 — intervention group
Group type: EXPERIMENTAL
Intervention: NMD after restoration of sinus rhythm at 1 month
Number of subjects: 46
Study 15632861 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratidine 10 mg daily for 7 days (group A)
Number of subjects: 20
Study 15632861 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratidine 10 mg daily for 7 days (group B)
Number of subjects: 20
Study 11165950 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 20 mg/day for 14 days, followed by placebo for 42 days
Number of subjects: 32
Study 11165950 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 20 mg/day for 14 days, followed by elemental calcium 1000 mg/day and placebo for 14 days, then by placebo for 28 days
Number of subjects: 32
Study 11165950 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 20 mg/day for 7 days, followed by elemental calcium 1000 mg/day and placebo for 21 days, then risedronate 20 mg/day for 7 days, and finally elemental calcium 1000 mg/day and placebo for 21 days
Number of subjects: 32
Study 11165950 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 56 days
Number of subjects: 32
Study 9708956 — intervention group
Group type: EXPERIMENTAL
Intervention: Apolipoprotein E ε4 carriers
Number of subjects: 405
Study 9708956 — intervention group
Group type: COMPARATOR
Intervention: Noncarriers of apoE ε4
Number of subjects: 405
Study 8069001 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFN beta ser)
Number of subjects: 372
Study 2742099 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2.5 micrograms/kg intravenously
Number of subjects: 40
Study 2742099 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) administered intravenously 8 minutes before induction
Number of subjects: 40
Study 951476 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation condition (air fluidized, ceramic bead bed in a light attenuating chamber)
Number of subjects: 40
Study 951476 — intervention group
Group type: COMPARATOR
Intervention: Non isolation condition
Number of subjects: 40
Study 30736402 — intervention group
Group type: EXPERIMENTAL
Intervention: REHIT
Number of subjects: 32
Study 30736402 — intervention group
Group type: COMPARATOR
Intervention: MICT
Number of subjects: 32
Study 28661955 — intervention group
Group type: EXPERIMENTAL
Intervention: STM+UC
Number of subjects: 100
Study 28661955 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 100
Study 26618458 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 times injection with 4 cc dose
Number of subjects: 24
Study 26618458 — intervention group
Group type: COMPARATOR
Intervention: 2 times injection with 6 cc dose
Number of subjects: 24
Study 22995453 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg/kg of EACA after induction, upon initiation of CPB, and after protamine.
Number of subjects: 120
Study 22995453 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg/kg of EACA after induction, followed by a maintenance infusion of 75 mg/kg/h until chest closure, and an additional 75 mg/kg upon initiation of CPB.
Number of subjects: 120
Study 22995453 — intervention group
Group type: COMPARATOR
Intervention: No antifibrinolytic agent or placebo (Control Group).
Number of subjects: 120
Study 21321298 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4922
Study 21321298 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4922
Study 19419824 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 32
Study 19419824 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 32
Study 17178496 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin resin (25%)
Number of subjects: 46
Study 17178496 — intervention group
Group type: EXPERIMENTAL
Intervention: Podophyllin resin (25%) together with acyclovir cream (5%)
Number of subjects: 46
Study 15095843 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideco DHF0.2
Number of subjects: 10
Study 15095843 — intervention group
Group type: EXPERIMENTAL
Intervention: Minntech Hemocor HPH 400
Number of subjects: 10
Study 11430636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofranil 25
Number of subjects: 18
Study 11430636 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofranil mite (10 mg)
Number of subjects: 18
Study 11430636 — intervention group
Group type: COMPARATOR
Intervention: Aqueous solution containing 25 mg imipramine-HCl
Number of subjects: 18
Study 9552905 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care testing
Number of subjects: 1728
Study 9552905 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care testing for haematological tests
Number of subjects: 1728
Study 9552905 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care testing for biochemical tests
Number of subjects: 1728
Study 9552905 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care testing for analyses of arterial blood gases
Number of subjects: 1728
Study 7512659 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum prostate specific antigen (PSA)
Number of subjects: 6630
Study 7512659 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 6630
Study 7512659 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PSA and digital rectal examination
Number of subjects: 6630
Study 7512659 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA
Number of subjects: 6630
Study 3219542 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at 10 pm
Number of subjects: 20
Study 3219542 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly selective vagotomy (HSV)
Number of subjects: 20
Study 3219542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31983236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 17160
Study 31983236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17160
Study 31291514 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided group (usual care guided by CRP point-of-care testing)
Number of subjects: 653
Study 31291514 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group (usual care alone)
Number of subjects: 653
Study 31291514 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP-guided group
Number of subjects: 653
Study 31291514 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 653
Study 29101325 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive social feedback from humanoid robot
Number of subjects: 44
Study 29101325 — intervention group
Group type: COMPARATOR
Intervention: Non-social positive feedback from humanoid robot
Number of subjects: 44
Study 29101325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive flexibility impairment and antipsychotic dosing
Number of subjects: 44
Study 25861013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 × 10 RE
Number of subjects: 27
Study 25861013 — intervention group
Group type: COMPARATOR
Intervention: 5 × 10 RE
Number of subjects: 27